InsiderSignal.AI

InsiderSignal.ai

LBRX - Lb Pharmaceuticals Inc

Insider Purchase by Deep Track Biotechnology Master Fund, Ltd. (10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Deep Track Biotechnology Master Fund, Ltd., serving as 10% owner at Lb Pharmaceuticals Inc (LBRX), purchased 2,666,666 shares at $15.00 per share, for a total transaction value of $39,999,990.00. Following this transaction, Deep Track Biotechnology Master Fund, Ltd. now holds 3,352,804 shares of LBRX.

This purchase represents a 389.00% increase in Deep Track Biotechnology Master Fund, Ltd.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, September 12, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, September 16, 2025, 4 days after the trade was made.

Lb Pharmaceuticals Inc operates in the NONE sector, specifically within the NONE industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Deep Track Biotechnology Master Fund, Ltd.

10%

Deep Track Biotechnology Master Fund, Ltd. is a Cayman Islands-registered hedge fund (LEI: 549300K3LAWQL6TAPO14) domiciled at 190 Elgin Avenue, George Town, KY1-9008, operating as an exempt company under the Cayman Islands Monetary Authority.[[2]](https://lei.bloomberg.com/leis/view/549300K3LAWQL6TAPO14)[[6]](https://www.lei-lookup.com/record/549300K3LAWQL6TAPO14/) It is managed by Deep Track Capital LP, a Greenwich, Connecticut-based investment firm founded in 2020 by David Kroin, who serves as Chief Investment Officer and Managing Member of the General Partner; the firm specializes exclusively in biotechnology and life sciences investments.[[1]](https://aum13f.com/fund/deep-track-biotechnology-master-fund-ltd)[[5]](https://www.sec.gov/Archives/edgar/data/1856083/000117266124004733/deeptrack-krro093024a1.htm)[[8]](https://radientanalytics.com/firm/adv/deep-track-capital-lp-312459)[[9]](https://www.deeptrackcapital.com) The fund, with a reported portfolio value of approximately $190-192 million and one current position, has engaged as a corporate insider, holding about 3,352,804 shares (10% ownership) in LB Pharmaceuticals Inc (LBRX) as a 10% beneficial owner, alongside activist stakes like 13.50% in Dynavax Technologies (DVAX).[[3]](https://fintel.io/i/deep-track-biotechnology-master-fund-ltd-7970)[[4]](https://www.gurufocus.com/insider/268108/deep-track-biotechnology-master-fund,-ltd.)[[7]](https://www.nasdaq.com/market-activity/insiders/deep-track-biotechnology-master-fund-ltd-1289637) Directors include David Kroin, Matt Auriemma, and Julie O'Hara, with custodians such as JP Morgan Prime Inc and Goldman Sachs & Co LLC.[[1]](https://aum13f.com/fund/deep-track-biotechnology-master-fund-ltd)

View full insider profile →

Trade Price

$15.00

Quantity

2,666,666

Total Value

$39,999,990.00

Shares Owned

3,352,804

Trade Date

Friday, September 12, 2025

163 days ago

SEC Filing Date

Tuesday, September 16, 2025

Filed 4 days after trade

NONENONE

About Lb Pharmaceuticals Inc

Company Overview

No company information available
View news mentioning LBRX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/363520

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime